SIRT3 and prostate carcinoma: Moreover, SIRT3 inhibits epithelial-mesenchymal transition (EMT) and migration by regulating FOXO3A expression and suppressing the Wnt/β-catenin pathway in prostate cancer (Li et al., 2018).